Developing the next generation of oncolytic immunotherapy

Replimune is developing the next generation of oncolytic immunotherapies using a proprietary new high potency backbone virus, which is engineered for oncolytic use (RP1). RP1 is itself expected to be a very potent activator of both innate and adaptive immune responses. RP1 is then used to deliver certain optimized immune activating proteins directly into the immune response-initiating tumor and to draining lymph nodes. This is expected to focus immune activation and potentiation on tumor antigens and reduce the toxicity often seen with systemic antibody based approaches.